Related Experiment Videos
Practical considerations for carbamazepine use in bipolar disorder
Matthew A Fuller1, Victor Dostrow, Sanjay Gupta
1Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10000 Brecksville Road, Brecksville, OH 44141, USA. mfuller64@comcast.net
Expert Opinion on Drug Safety
|June 16, 2006
Summary
Carbamazepine (CBZ) is effective for epilepsy and bipolar disorder. While common side effects like fatigue occur, serious adverse events are rare, making CBZ a viable psychiatric treatment with proper monitoring.
Area of Science:
- Pharmacology
- Neurology
- Psychiatry
Background:
- Carbamazepine (CBZ) is a well-established antiepileptic drug with a characterized safety profile.
- An extended-release formulation (CBZ-ERC) is now approved for bipolar disorder treatment.
Purpose of the Study:
- To review the safety and tolerability of carbamazepine, particularly its extended-release formulation, for psychiatric use.
- To highlight key adverse events and monitoring considerations for CBZ in patient populations.
Main Methods:
- Review of existing literature on carbamazepine's efficacy and safety.
- Analysis of adverse event profiles, including common and rare serious effects.
- Consideration of formulation-specific characteristics (extended-release).
Main Results:
- Common adverse events include somnolence, fatigue, dizziness, and headache.
- Rash and leukopenia occur in about 10% of patients but are typically benign.
- Rare serious risks include agranulocytosis, aplastic anemia, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
Conclusions:
- Carbamazepine, especially its extended-release form, presents a manageable safety profile for psychiatric disorders like bipolar disorder.
- Careful patient monitoring and dose titration are crucial for optimizing CBZ therapy and mitigating risks.
- Hyperglycemia and significant weight gain are not typical concerns with CBZ treatment.